Showing results (261-270 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
The Lancet. Oncology|May 13, 2017
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trialAngela Alistar, Bonny B Morris, Rodwige Desnoyer, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
The Lancet. Oncology|April 4, 2018
Medication overuse in oncology: current trends and future implications for patients and societyStephen M Schleicher, Peter B Bach, Konstantina Matsoukas, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
The Lancet. Oncology|May 1, 2017
Proton therapy for head and neck cancer: expanding the therapeutic windowJonathan E Leeman, Paul B Romesser, Ying Zhou, et al.
The Lancet. Oncology|September 21, 2016
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trialAndrew J Yee, William I Bensinger, Jeffrey G Supko, et al.
The Lancet. Oncology|September 7, 2016
Imaging oligometastatic cancer before local treatmentJames M Franklin, Ricky A Sharma, Adrian L Harris, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Pageof 336